Comparative Pharmacology
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus POLYSPORIN.
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus POLYSPORIN.
ELASE-CHLOROMYCETIN vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Topical application: Apply thin layer to affected area 2-3 times daily.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic and Debriding Agent
Topical Antibiotic